Vaginal Mesh Lawsuit: 2026 Settlement Amounts, Eligibility, and Current Case Status

Women who suffered mesh erosion, chronic pain, or organ damage after a vaginal mesh implant may still qualify for a vaginal mesh lawsuit in 2026, even though the seven federal multidistrict litigations that once consolidated more than 107,000 cases have closed. Manufacturers including Ethicon (Johnson & Johnson), Boston Scientific, C.R. Bard, American Medical Systems, and Coloplast have paid out more than $8 billion combined to resolve transvaginal mesh claims. New claims are now filed mainly in state court, including active multicounty litigation in New Jersey, and eligibility depends on your state's statute of limitations and when your injury was discovered.

Vaginal mesh, also called transvaginal mesh or pelvic mesh, is a surgical implant made largely of polypropylene, a synthetic plastic. Surgeons have used it since the 1990s and 2000s to treat pelvic organ prolapse (POP), a condition in which pelvic organs sag into the vaginal canal, and stress urinary incontinence (SUI).

Vaginal mesh lawsuits allege that manufacturers sold these devices with defective designs and inadequate warnings, and that companies knew or should have known about high complication rates from internal testing and adverse event reports before marketing the products as safe. Plaintiffs also allege negligence, failure to warn, and, in some cases, deceptive marketing to physicians and patients.

The U.S. Food and Drug Administration (FDA) reclassified transvaginal mesh for POP repair as a Class III, or high-risk, device in 2016. On April 16, 2019, the FDA ordered Boston Scientific and Coloplast, the last two manufacturers still selling POP mesh, to immediately stop selling and distributing those products after determining their premarket approval applications did not show reasonable assurance of safety and effectiveness. Mesh slings used specifically for stress urinary incontinence were not included in that order and remain available.

Combined across all manufacturers, industry settlement tracking cited by legal publisher Drugwatch put total transvaginal mesh payouts at more than $8 billion as of June 2026. Because many individual settlements are confidential, the true combined total is likely higher.

A small number of jury verdicts have reached into the millions or tens of millions of dollars, but these are outliers, not typical outcomes, and many large verdicts are later reduced or overturned on appeal. Treat any "average settlement" figure with caution: it depends heavily on which cases are included in the calculation.

Vaginal mesh cases were never true class actions. They were coordinated as multidistrict litigation (MDL), a federal process that centralizes similar individual lawsuits before one judge for pretrial proceedings while each case keeps its own facts, injuries, and eventual settlement value. New Jersey's mesh dockets are multicounty litigation (MCL), the state-court equivalent. Each plaintiff's compensation is still determined individually, even within these coordinated proceedings.